- Home
- TTNP vs REVB Comparison
TTNP vs REVB Comparison
Compare TTNP & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- REVB
- Stock Information
- Founded
- TTNP 1991
- REVB 2020
- Country
- TTNP United States
- REVB United States
- Employees
- TTNP N/A
- REVB N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- REVB Health Care
- Exchange
- TTNP Nasdaq
- REVB Nasdaq
- Market Cap
- TTNP 3.4M
- REVB 2.8M
- IPO Year
- TTNP 1996
- REVB N/A
- Fundamental
- Price
- TTNP $3.70
- REVB $2.92
- Analyst Decision
- TTNP
- REVB
- Analyst Count
- TTNP 0
- REVB 0
- Target Price
- TTNP N/A
- REVB N/A
- AVG Volume (30 Days)
- TTNP 9.7K
- REVB 146.9K
- Earning Date
- TTNP 05-14-2025
- REVB 05-09-2025
- Dividend Yield
- TTNP N/A
- REVB N/A
- EPS Growth
- TTNP N/A
- REVB N/A
- EPS
- TTNP N/A
- REVB N/A
- Revenue
- TTNP N/A
- REVB N/A
- Revenue This Year
- TTNP N/A
- REVB N/A
- Revenue Next Year
- TTNP N/A
- REVB N/A
- P/E Ratio
- TTNP N/A
- REVB N/A
- Revenue Growth
- TTNP N/A
- REVB N/A
- 52 Week Low
- TTNP $3.03
- REVB $2.36
- 52 Week High
- TTNP $14.80
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- TTNP 49.54
- REVB 45.77
- Support Level
- TTNP $3.53
- REVB $2.76
- Resistance Level
- TTNP $3.76
- REVB $3.62
- Average True Range (ATR)
- TTNP 0.20
- REVB 0.41
- MACD
- TTNP -0.00
- REVB 0.02
- Stochastic Oscillator
- TTNP 32.79
- REVB 34.12
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).